Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Galera Therapeutics
Biotech
Galera lays off 70% as radiotherapy complication drug rejected
Galera Therapeutics has slammed the emergency button and watched its stock sink in the wake of a complete response letter from the FDA.
James Waldron
Aug 10, 2023 8:19am
Novartis R&D chief Jay Bradner departs—Chutes & Ladders
Sep 2, 2022 9:30am
Galera shares rise over 100% as phase 3 flop deemed an error
Dec 14, 2021 3:30pm
Galera shares slide as radiotherapy complication drug fails
Oct 19, 2021 11:53am
Galera reels in $150M to test radiation side effect med in phase 3
Sep 19, 2018 11:10am
Poised for phase 3, Galera's GC4419 wards off radiation side effects
Aug 20, 2018 5:00am